Oxford Biomedica Solutions forms new partnerships with three biotechnology companies
2022-12-14
Oxford Biomedica Solutions forms new partnerships with three biotechnology companies
Agreements signed with three new partners, bringing the total number of new partners in 2022 to four, ahead of original target
BEDFORD, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Oxford Biomedica Solutions LLC, an AAV manufacturing and innovation company, announced today that it has signed agreements with three additional U.S. based, biotechnology companies. This places Oxford Biomedica Solutions ahead of the previously stated target of two new partners by the end of the calendar year.
Under these additional agreements, Oxford Biomedica Solutions will provide its full platform offering to support the new partners’ gene therapy programs, which cover a broad range of indications, including CNS, autoimmune, oncology, muscular, and rare metabolic disease. Oxford Biomedica Solutions’ proven platform has demonstrated consistent bioreactor titers of E15 vg/L and achieved over 90% fully intact vector for multiple constructs.
Oxford Biomedica Solutions’ innovative platform potentially enables accelerated drug development of high quality products produced at significantly more doses per batch. The platform drives down the number of batches needed, as well as the cost, for both clinical and commercial operations, to deliver much needed therapies to patients sooner. In line with preparing and managing the increasing activities and demand, we have recently opened a new 24,000sqft expansion space that includes dedicated analytical development lab space to accommodate the growth in new projects and partners, as well as continued development innovation. Additionally, this new space will also house a commercial GMP Drug Substance footprint that will incorporate multiple 500L bioreactors and allow Oxford Biomedica Solutions to offer a single facility option for both clinical and commercial supply of high quality and high titer vector.
Tim Kelly, Chair and CEO of Oxford Biomedica Solutions, said, “These new partnerships are a true validation of the Oxford Biomedica Solutions team, our capabilities, and AAV plug-and-play platform. We started this endeavor because we were confident that we can help develop successful gene therapy products with our platform, expertise, and the care that our team delivers on every product. We are excited this is now coming to fruition, and we are giving our new partners and their patients access to high quality product with the efficiency and productivity of our platform addressing the increase in demand that we are seeing.”
Contact:
T: +1 781.428.4536 / E: solutions.partnering@oxb.com
Kelly Quesada, Senior VP Strategy and Business Operations
Oxford Biomedica Solutions offers a platform that can achieve both high titer and high product quality vector for partners. The platform has already been proven with six separate new product INDs and CTAs. High titer, high product quality, proven expertise, and speed are the foundation of the platform. This unique platform and fully integrated end-to-end capabilities, from vector design and process development through to clinical trials, are now available to partners. For more information contact us at solutions.partnering@oxb.com or visit our website at oxbsolutions.com.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。